Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, California, USA.
Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Am J Transplant. 2022 Sep;22(9):2195-2202. doi: 10.1111/ajt.17079. Epub 2022 May 13.
"Sarcopenic obesity" refers to a condition of low muscle mass in the context of obesity, though may be difficult to assess in patients with cirrhosis who are acutely ill. We aimed to define sarcopenic visceral obesity (SVO) using CT-based skeletal muscle index (SMI) and visceral-to-subcutaneous adipose tissue ratio (VSR) to examine its association with post-transplant mortality. We analyzed 116 adult inpatients with cirrhosis who were urgently listed and transplanted between 1/2005 and 12/2017 at 4 North American transplant centers. SVO was defined as patients with sarcopenia (SMI <50 cm /m in men and <39 cm /m in women) and visceral obesity (VSR ≥ 1.54 in men and ≥1.37 in women). The percentage who met criteria for sarcopenia, visceral obesity, and SVO were 45%, 42%, and 20%, respectively. Cumulative rates of post-transplant mortality were higher in patients with SVO compared to patients with sarcopenia or visceral obesity alone at 36 months (39% vs. 14% vs. 8%) [logrank p = .01]. In univariable regression, SVO was associated with post-transplant mortality (HR 2.92, 95%CI 1.04-8.23) and remained significant after adjusting for age, sex, diabetes, encephalopathy, hepatocellular carcinoma, and MELD-Na (HR 3.50, 95%CI 1.10-11.15). In conclusion, SVO is associated with increased post-transplant mortality in acutely ill patients with cirrhosis.
"肌少症性肥胖"是指肥胖患者的肌肉量低,但对于患有急性疾病的肝硬化患者,可能难以评估。我们旨在使用基于 CT 的骨骼肌指数 (SMI) 和内脏脂肪与皮下脂肪组织比 (VSR) 来定义肌少性内脏肥胖 (SVO),并检查其与移植后死亡率的关系。我们分析了 2005 年 1 月至 2017 年 12 月在北美 4 个移植中心紧急列出并进行移植的 116 名成年肝硬化住院患者。将 SVO 定义为患有肌少症 (男性 SMI<50cm/m,女性 SMI<39cm/m) 和内脏肥胖 (男性 VSR≥1.54,女性 VSR≥1.37) 的患者。符合肌少症、内脏肥胖和 SVO 标准的患者比例分别为 45%、42%和 20%。在 36 个月时,SVO 患者的移植后死亡率高于仅患有肌少症或内脏肥胖的患者,分别为 39%、14%和 8%[logrank p=0.01]。在单变量回归中,SVO 与移植后死亡率相关 (HR 2.92,95%CI 1.04-8.23),在调整年龄、性别、糖尿病、肝性脑病、肝细胞癌和 MELD-Na 后仍然显著 (HR 3.50,95%CI 1.10-11.15)。总之,SVO 与肝硬化急性疾病患者的移植后死亡率增加有关。